Precirix

TLDR

Precirix is a Brussels-based clinical-stage biotech developing radiopharmaceuticals for cancer treatment, targeting solid tumors with targeted radionuclide therapy.

Overview

Precirix is headquartered in Brussels and is developing targeted radionuclide therapies for cancer. The company's approach uses nanobodies, small antibody fragments, to deliver radioactive payloads directly to tumor cells while minimizing damage to surrounding healthy tissue. This class of therapy is known as radiopharmaceutical therapy or targeted radionuclide therapy.

Precirix operates at the clinical stage, meaning its programs are in human trials. The radiopharmaceutical sector has seen strong interest from large pharma companies following the success of approved therapies from companies such as Novartis, driving deal activity in the space globally.